NYSEAMERICAN:PTN - Palatin Technologies Stock Price, Forecast & News

Palatin Technologies trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PTN."

Palatin Technologies, Inc. (NYSEAMERICAN:PTN) released its earnings results on Wednesday, November, 13th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.02). The biopharmaceutical company earned $0.10 million during the quarter, compared to analysts' expectations of $3.28 million. During the same period in the prior year, the company earned ($0.03) earnings per share. View Palatin Technologies' Earnings History.

Palatin Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 11th 2020. View Earnings Estimates for Palatin Technologies.

3 brokers have issued 12-month target prices for Palatin Technologies' shares. Their forecasts range from $3.00 to $7.50. On average, they anticipate Palatin Technologies' share price to reach $5.50 in the next twelve months. This suggests a possible upside of 595.1% from the stock's current price. View Analyst Price Targets for Palatin Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Palatin Technologies in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Palatin Technologies.

News articles about PTN stock have trended very negative on Friday, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Palatin Technologies earned a news sentiment score of -3.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the company's share price in the immediate future. View News Stories for Palatin Technologies.

Some companies that are related to Palatin Technologies include Integral Diagnostics (IDX), Volpara Health Tech (VHT), Akumin (AKU), Exagen (XGN), Senseonics (SENS), Renalytix Ai (RENX), Profound Medical (PRN), DermTech (DMTK), Oncosil Medical (OSL), Yourgene Health (YGEN), MaxCyte (MXCT), Lexagene (LXG), BARD1 Life Sciences (BD1), Sernova (SVA) and Oncimmune (ONC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Palatin Technologies investors own include 22nd Century Group (XXII), Heat Biologics (HTBX), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), ImmunoGen (IMGN), Progenics Pharmaceuticals (PGNX), Actinium Pharmaceuticals (ATNM), AVEO Pharmaceuticals (AVEO), AcelRx Pharmaceuticals (ACRX) and AMAG Pharmaceuticals (AMAG).

Palatin Technologies' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.51%), California Public Employees Retirement System (0.26%), First Trust Advisors LP (0.20%), Barclays PLC (0.04%), Commonwealth Equity Services LLC (0.03%) and Meeder Asset Management Inc. (0.03%). Company insiders that own Palatin Technologies stock include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Institutional Ownership Trends for Palatin Technologies.

PTN stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for Palatin Technologies.

PTN stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State Street Corp, Meeder Asset Management Inc., Commonwealth Equity Services LLC, California Public Employees Retirement System and Summit X LLC. Company insiders that have bought Palatin Technologies stock in the last two years include Alan W Dunton, Arlene Morris, Carl Spana, Joseph Stanley Hull, Robert K Deveer Jr and Stephen T Wills. View Insider Buying and Selling for Palatin Technologies.

Shares of PTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PTN stock can currently be purchased for approximately $0.79.

Palatin Technologies has a market capitalization of $181.28 million. Palatin Technologies employs 19 workers across the globe.View Additional Information About Palatin Technologies.

The official website for Palatin Technologies is http://www.palatin.com/.

Palatin Technologies' mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company can be reached via phone at +1-609-4952200.